Results 141 to 150 of about 304,927 (291)

Mass spectrometry based identification of AMP‐O‐Tris generated by Thermococcus onnurineus Cas10

open access: yesFEBS Open Bio, EarlyView.
Isolated Thermococcus onnurineus Cas10 generates the noncanonical ATP‐derived product AMP‐O‐Tris while in Tris‐containing buffer as identified via mass spectrometry, revealing relaxed nucleophile selectivity under isolated conditions. These findings suggest that multiprotein Csm complex assembly restricts Cas10 reactivity toward canonical cyclic ...
Su‐Jin Lee   +6 more
wiley   +1 more source

Enzymatic and microbial routes to bioplastics: The green chemistry frontier of biopolymers

open access: yesFEBS Open Bio, EarlyView.
Microbial biosynthesis and engineered enzyme platforms are expanding the design space of polyhydroxyalkanoate bioplastics. By combining fermentation, PHA synthase engineering and cell‐free modular systems, tailored biodegradable polymers can be produced with tunable properties, supporting more sustainable materials and future circular bioeconomy ...
Giovanni Gallo   +4 more
wiley   +1 more source

Press review.

open access: yesBlood transfusion = Trasfusione del sangue, 2007
openaire   +3 more sources

Re‐Awakening Public Attention to the Silent Pandemic of Cancer Among Older Adults in Low‐ and Middle‐Income Countries

open access: yesAging and Cancer, EarlyView.
ABSTRACT As global populations age, cancer is increasingly becoming a leading cause of morbidity and mortality among older adults, particularly in low‐ and middle‐income countries (LMICs). Despite accounting for the majority of new cancer cases and deaths, older individuals remain underrepresented in cancer research, clinical guidelines, and health ...
Ibrahim Bidemi Abdullateef   +2 more
wiley   +1 more source

RESEARCHING THE PROCESS OF HOLLOW PROFILE SETTING- PRESSING OF A COMPOSITE MATERIAL BASED ON METALLIC POWDERS

open access: green, 2015
L. S. Kokhan   +9 more
openalex   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy